Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/07/25	14.50 $	-2.42%	644,390
17/07/25	14.86 $	-2.81%	1,055,577
16/07/25	15.29 $	+11.61%	1,357,414
15/07/25	13.70 $	-6.68%	813,626
14/07/25	14.68 $	-0.47%	1,074,383

Delayed Quote Nasdaq, 19 July 2025 at 06:00 am AEST

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 06:00:00 19/07/25 am AEST			5-day change	1st Jan Change
14.50 ^USD	-2.42%		-1.69%	+11,053.85%

01/07	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
30/06	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI

Capitalization	8.43B 7.23B 6.74B 6.27B 11.56B 726B 12.91B 81.38B 30.72B 340B 31.61B 30.95B 1,251B	P/E ratio 2023	-51.1x	P/E ratio 2024	-10.2x
Enterprise value	8.42B 7.22B 6.73B 6.26B 11.55B 725B 12.9B 81.3B 30.69B 340B 31.58B 30.92B 1,249B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	11.18%	Yield 2023 *	-	Yield 2024	-

Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	01/07	CI
Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	30/06	CI
Top Premarket Gainers	25/06	MT
Top Premarket Decliners	23/06	MT
Top Premarket Decliners	20/06	MT
Top Premarket Decliners	18/06	MT
Top Premarket Gainers	17/06	MT
Regencell Bioscience Extends Gains Pre-Bell Tuesday Following 276% Surge Monday	17/06	MT
Top Premarket Gainers	16/06	MT
Regencell Bioscience Approves 38-For-One Forward Stock Split	02/06	RE
Top Premarket Gainers	18/03	MT
Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2024	26/10/24	CI
Top Premarket Decliners	29/07/24	MT

Regencell Bioscience : Announces First Half 2024 Financial Results Form 6 K	20/06/24	PU
Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K	02/01/24	PU
Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K	15/12/23	PU
Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K	16/06/23	PU
Regencell Bioscience : Changes in Registrant’s Certifying Accountant - Form 6-K	17/03/23	PU

Regencell Bioscience Holdings Limited Stock

Equities

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada	28/06
La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...	18/02/22
La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...	18/02/22
Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen	18/02/22
Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días	18/02/22

1 day	-2.42%
1 week	-1.69%
Current month	-14.91%
1 month	-77.11%
3 months	+1,792.21%
6 months	+11,335.33%
Current year	+11,053.85%

1 week	13.54	16.68
1 month	9.39	34.58
Current year	0.09	83.6
1 year	0.08	83.6
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	-	-
Wai Hong Chung COO	Chief Operating Officer	48	01/08/2021

Director	Title	Age	Since
Wai Hong Chung BRD	Director/Board Member	48	28/12/2023
Yee Wah Hui BRD	Director/Board Member	53	01/07/2021
Paul Niewiadomski BRD	Director/Board Member	55	01/07/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-2.42%	-1.69%	+16,011.11%	+1,326.32%	7.17B
LONZA GROUP AG	-0.04%	+1.03%	+10.09%	+1.28%	50.35B
BEONE MEDICINES LTD.	+1.45%	+17.68%	+90.35%	+65.14%	34.95B
CELLTRION, INC.	-0.06%	+0.95%	+4.78%	+11.89%	28.67B
IQVIA HOLDINGS INC.	-1.60%	-1.33%	-28.47%	-27.15%	27.79B
EUROFINS SCIENTIFIC SE	+1.19%	+1.25%	+26.23%	-21.75%	12.81B
ICON PUBLIC LIMITED COMPANY	-2.27%	-4.64%	-56.46%	-32.78%	11.41B
TEMPUS AI, INC.	+0.54%	+7.21%	+47.29%	-	10.56B
QIAGEN N.V.	+0.25%	+0.48%	+13.16%	-3.05%	10.47B
ASCENDIS PHARMA A/S	-4.12%	-2.89%	+25.66%	+93.20%	10.29B
Average	-0.71%	+1.04%	+1,614.37%	+157.01%	20.45B
Weighted average by Cap.	-0.29%	+3.07%	+579.09%	+60.40%

	2023	2024
Net sales	-	-
Net income	-5.87M -5.04M -4.69M -4.37M -8.06M -506M -9M -56.7M -21.4M -237M -22.02M -21.57M -871M	-4.3M -3.69M -3.44M -3.2M -5.9M -370M -6.59M -41.55M -15.68M -174M -16.14M -15.8M -639M
Net Debt	-11.1M -9.52M -8.87M -8.26M -15.23M -956M -17.01M -107M -40.47M -448M -41.64M -40.78M -1.65B	-7.88M -6.76M -6.3M -5.86M -10.81M -678M -12.07M -76.06M -28.71M -318M -29.54M -28.93M -1.17B